Literature DB >> 30801195

Freeze-Drying To Produce Efficacious CPMV Virus-like Particles.

Yi Zheng, Parker W Lee, Chao Wang, Linda D Thomas, Phoebe L Stewart, Nicole F Steinmetz, Jonathan K Pokorski.   

Abstract

In situ cancer vaccination that uses immune stimulating agents is revolutionizing the way that cancer is treated. In this realm, viruses and noninfectious virus-like particles have gained significant traction in reprogramming the immune system to recognize and eliminate malignancies. Recently, cowpea mosaic virus-like particles (VLPs) have shown exceptional promise in their ability to fight a variety of cancers. However, the current methods used to produce CPMV VLPs rely on agroinfiltration in plants. These protocols remain complicated and labor intensive and have the potential to introduce unwanted immunostimulatory agents, like lipopolysaccharides. This Letter describes a simple "post-processing" method to remove RNA from wild-type CPMV, while retaining the structure and function of the capsid. Lyophilization was able to eject encapsulated RNA to form lyo-eCPMV and, when purified, eliminated nearly all traces of encapsulated RNA. Lyo-eCPMV was characterized by cryo-electron microscopy single particle reconstruction to confirm the structural integrity of the viral capsid. Finally, lyo-eCPMV showed  equivalent anticancer efficacy as eCPMV, produced by agroinfiltration, when using an invasive melanoma model. These results describe a straightforward method to prepare CPMV VLPs from infectious virions.

Entities:  

Keywords:  Virus-like particle; immunotherapy; in situ vaccine; lyophilization; therapeutic protein

Mesh:

Substances:

Year:  2019        PMID: 30801195      PMCID: PMC7272238          DOI: 10.1021/acs.nanolett.9b00300

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  27 in total

1.  EMAN2: an extensible image processing suite for electron microscopy.

Authors:  Guang Tang; Liwei Peng; Philip R Baldwin; Deepinder S Mann; Wen Jiang; Ian Rees; Steven J Ludtke
Journal:  J Struct Biol       Date:  2006-06-08       Impact factor: 2.867

Review 2.  Production methods for viral particles.

Authors:  Kodai Machida; Hiroaki Imataka
Journal:  Biotechnol Lett       Date:  2014-12-09       Impact factor: 2.461

Review 3.  Lipopolysaccharide structures from Agrobacterium and Rhizobiaceae species.

Authors:  Cristina De Castro; Antonio Molinaro; Rosa Lanzetta; Alba Silipo; Michelangelo Parrilli
Journal:  Carbohydr Res       Date:  2008-02-02       Impact factor: 2.104

Review 4.  The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment.

Authors:  Giorgio Bogani; Umberto Leone Roberti Maggiore; Mauro Signorelli; Fabio Martinelli; Antonino Ditto; Ilaria Sabatucci; Lavinia Mosca; Domenica Lorusso; Francesco Raspagliesi
Journal:  Crit Rev Oncol Hematol       Date:  2017-12-28       Impact factor: 6.312

5.  CTFFIND4: Fast and accurate defocus estimation from electron micrographs.

Authors:  Alexis Rohou; Nikolaus Grigorieff
Journal:  J Struct Biol       Date:  2015-08-13       Impact factor: 2.867

Review 6.  Oncolytic viruses as therapeutic cancer vaccines.

Authors:  David L Bartlett; Zuqiang Liu; Magesh Sathaiah; Roshni Ravindranathan; Zongbi Guo; Yukai He; Zong Sheng Guo
Journal:  Mol Cancer       Date:  2013-09-11       Impact factor: 27.401

7.  In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer.

Authors:  P H Lizotte; A M Wen; M R Sheen; J Fields; P Rojanasopondist; N F Steinmetz; S Fiering
Journal:  Nat Nanotechnol       Date:  2015-12-21       Impact factor: 39.213

8.  Genetic engineering and characterization of Cowpea mosaic virus empty virus-like particles.

Authors:  Frank Sainsbury; Pooja Saxena; Alaa A A Aljabali; Keith Saunders; David J Evans; George P Lomonossoff
Journal:  Methods Mol Biol       Date:  2014

9.  RELION: implementation of a Bayesian approach to cryo-EM structure determination.

Authors:  Sjors H W Scheres
Journal:  J Struct Biol       Date:  2012-09-19       Impact factor: 2.867

10.  The structures of a naturally empty cowpea mosaic virus particle and its genome-containing counterpart by cryo-electron microscopy.

Authors:  Emma L Hesketh; Yulia Meshcheriakova; Rebecca F Thompson; George P Lomonossoff; Neil A Ranson
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

View more
  6 in total

1.  Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model.

Authors:  Edward C Koellhoffer; Chenkai Mao; Veronique Beiss; Lu Wang; Steven N Fiering; Christine E Boone; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2022-01-03       Impact factor: 5.364

Review 2.  The pharmacology of plant virus nanoparticles.

Authors:  Christian Isalomboto Nkanga; Nicole F Steinmetz
Journal:  Virology       Date:  2021-01-28       Impact factor: 3.616

Review 3.  Virus-like Particles as Preventive and Therapeutic Cancer Vaccines.

Authors:  Anna Lucia Tornesello; Maria Tagliamonte; Franco M Buonaguro; Maria Lina Tornesello; Luigi Buonaguro
Journal:  Vaccines (Basel)       Date:  2022-02-02

4.  Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate.

Authors:  Christian Isalomboto Nkanga; Oscar A Ortega-Rivera; Matthew D Shin; Miguel A Moreno-Gonzalez; Nicole F Steinmetz
Journal:  Biomacromolecules       Date:  2022-03-28       Impact factor: 6.988

5.  Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature.

Authors:  Kara-Lee Aves; Christoph M Janitzek; Cyrielle E Fougeroux; Thor G Theander; Adam F Sander
Journal:  Pharmaceutics       Date:  2022-06-18       Impact factor: 6.525

6.  The unique potency of Cowpea mosaic virus (CPMV) in situ cancer vaccine.

Authors:  Sourabh Shukla; Chao Wang; Veronique Beiss; Hui Cai; Torus Washington; Abner A Murray; Xingjian Gong; Zhongchao Zhao; Hema Masarapu; Adam Zlotnick; Steven Fiering; Nicole F Steinmetz
Journal:  Biomater Sci       Date:  2020-09-30       Impact factor: 7.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.